Erectile dysfunction in hemodialysis: A systematic review

Ahmed El-Assmy

Ahmed El-Assmy, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt
Author contributions: El-Assmy A solely contributed to this manuscript.
Correspondence to: Ahmed El-Assmy, Associate Professor of Urology, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. a_assmy@yahoo.com
Telephone: +20-50-2262222 Fax: +20-50-2263717
Received: August 19, 2011 Revised: June 12, 2012
Accepted: September 25, 2012
Published online: December 6, 2012

Abstract

Men with chronic renal failure (CRF) on hemodialysis have been frequently associated with erectile dysfunction (ED), with an of between 20% to 87.7%. As a result of the multi-system disease processes present in many uremic men, it is apparent that the pathogenesis of ED is most probably multifactorial. Factors to be considered include peripheral vascular disease, neurogenic abnormalities, hormonal disturbances and medications used for treatment of conditions associated with CRF. These physiological abnormalities may be supplemented by significant psychological stresses and abnormalities resulting from chronic illness. Treatment must start with the determination and treatment of the underlying causes. In addition to psychological treatment, further lines of treatment of ED in CRF can be classified as 1st line (medical treatment which includes oral phosphodiesterase-5 inhibitors and hormone regulation), 2nd line (intracavernosal injection, vacuum constriction devices and alprostadil urethral suppositories) or 3rd line (surgical treatment). Renal transplantation improves the quality of life for some patients with CRF and subsequently it may improve erectile function in a significant number of them, however still there is high incidence of ED after transplantation.

Key words: Erectile dysfunction; Haemodialysis; Risk factor; Treatment; Renal failure

Peer reviewer: Biagio Raffaele Di Iorio, MD, PhD, Department of Medicine, UOC of Nephrology, “A. Landolfi Hospital”, Via Melito, snc, I-83100 Solofra (AV), Italy

© 2012 Baishideng. All rights reserved.

INTRODUCTION

Life expectancy for patients with chronic renal failure (CRF) has been extended as a result of improvements in dialysis therapy. Together with the introduction of new effective oral erectogenic drugs, these accomplishments have led to a new appreciation of problems previously ignored that affect the well-being and the quality of life of patients with CRF. One of these problems is erectile dysfunction (ED), a common feature of end stage renal disease (ESRD). ED is frequently associated with men with CRF; the incidence is variable between 20% and 87.7%.

PATHOGENESIS OF ERECTILE DYSFUNCTION IN CRF

The pathogenesis of ED in CRF is often multifactorial and is primarily organic in origin. Factors to be considered include peripheral vascular disease, neurogenic abnormalities, hormonal disturbances and medications used for treatment of conditions associated with CRF. These physiological abnormalities may be supplemented by significant psychological stresses and abnormalities resulting from chronic illness and generalized changes in body function.
**Vasculogenic factors**

Vasculogenic factors can be divided into arterial insufficiency and veno-occlusive dysfunction (VOD). Arterial insufficiency is an important cause of ED in CRF. It is well known that patients with uremia on chronic hemodialysis have accelerated atherosclerosis affecting both large and small vessels and vasculogenic impotence could be suspected in these patients regardless of age. Kaufman et al. found cavernous artery occlusive disease in 78% of uremic patients. This renal failure-associated vascular disease of the penis was found to occur independently of the presence of known systemic atherosclerotic vascular risk factors. Patients who underwent early treatment of the uremia by renal transplantation had vasculogenic ED only in the case of rejection of the renal transplant, suggesting that early renal transplantation may delay or prevent the development of the penile vasculopathy.

As a result of recent developments in the understanding of the physiology of ED, not only arterial inflow but also venous outflow abnormalities must be considered in the vascular assessment of ED. In one study VOD was found in 90% of impotent CRF patients. The explanation of VOD is based on CRF associated hypoxia. Two distinct sources for the hypoxia in ESRD have been identified: a pulmonary-associated hypoxia based on hypoventilation and pulmonary microembolization and an anemia-associated hypoxia based on diminished erythropoietin production. Hypoxia has been shown to reduce nitric oxide synthase (NOS) mRNA expression and to decrease the activity of the enzyme NOS. In addition, hypoxia has been found to increase transforming growth factor B1, which increases collagen synthesis with subsequent fibrosis and decrease tissue compliance. Such hypoxia-induced fibrotic structural changes in the erectile tissue may impair vascular compliance that would lead to VOD (Figure 1).

**Neurogenic factors**

Autonomic control of erectile smooth muscle tissue is critical in the maintenance of erectile function. Autonomic dysfunction is common in metabolic disorders, such as CRF. Impotence, postural dizziness, gastric fullness or delay in emptying, bowel dysfunction, and reduced sweating are the most common symptoms due to autonomic dysfunction. Peripheral neuropathy is another cause of neurogenic ED in such group of patients.

**Pharmacological factors**

Some medications given to uremic patients may be implicated in the pathogenesis of ED. Several antihypertensive agents are known to cause sexual problems or exacerbate existing problems. However, not all classes of antihypertensive agents share the same risk of inducing sexual problems, and certain classes of antihypertensive agents tend to be associated with a higher prevalence of sexual dysfunction than others. A higher incidence of ED has been reported in some studies of diuretics, including spironolactone and thiazides, β blockers as well as centrally acting antiadrenergic agents, such as methyldopa and clonidine. Few studies were found within the literature that evaluated the association between the existence of ED in CRF patients and the use of antihypertensive drugs. Rodger showed that there was no relationship between the two phenomena. Cerqueira et al. found that ED was of equal frequency among patients using antihypertensive drugs and those that were not (26% vs 21%).

Histamine-2 receptor antagonists, particularly cimetidine, carry a high risk for causing ED due to increased plasma prolactin levels. More modern anti-ulcer drugs (e.g., proton pump inhibitors) do not appear to be associated with the same risk factor. In addition, psychotropic drugs that may be used for treatment of depression can cause ED by influencing central nervous system mechanisms.

**Psychological factors**

The psychological impact of uremia has a significant role in ED in patients with CRF. Patients with uremia especially those on hemodialysis, have a significant incidence of psychiatric and depressive illnesses compared with the normal population. The etiology of depression in patients with ESRD is usually associated with several losses. These include loss of kidney function, well being, place in family and workplace, financial resources, and of sexual function. Also the higher incidence of depression may be related to the problems of dependence on the machine, the problems of obtaining a kidney donor and worries about an uncertain future.

Depression may be difficult to diagnose in patients with ESRD. This is due, at least in part, to the overlap between the symptoms of depression and those of uremic dysfunction.
mia. Symptoms of depression include sleep disturbance, depressed mood, appetite disturbances or weight change, problems in concentration, psychomotor agitation or depression, fatigue, feelings of guilt, worthlessness, loss of interest in life or pleasure, and recurrent thoughts of death or suicidal tendency. There is a well-established association between depression, its severity and ED. Procci et al. have identified a higher incidence of depressive episodes in patients on hemodialysis than in a normal population. Cerqueira and associates evaluated 119 patients with CRF and on hemodialysis and found that of the patients who had depression, 34.8% had ED. When the regression analysis was performed, psycho-emotional factors persisted in the final model, showing a strong relationship with ED.

**Endocrine factors**

The kidney plays an integral role in endocrine function. In men with CRF, disturbances in the pituitary-gonadal axis can be detected with only moderate reductions in the GFR and progressively worsen as renal failure progresses. Total and free testosterone levels are typically reduced. Low testosterone levels are most probably caused by decreased testosterone production, although there is evidence for elevated metabolic clearance of testosterone in addition to decreased production.

Another proposed endocrine cause of ED in patients with CRF is hyperprolactinemia which is identified in more than 50% of CRF patients on dialysis. Increased prolactin secretion in CRF may be related in part to the development of secondary hyperparathyroidism, depletion of total body zinc and to medications used in patients with CRF, such as methyldopa, digoxin, cimetidine and metoclopramide. The mechanism by which increased levels of prolactin may cause ED is not well defined; an alteration in libido in such patients may be the cause of ED. On the other hand, some authors have shown that there is no correlation between ED and hyperprolactinemia in patients with CRF on hemodialysis.

Other endocrine abnormalities, especially diabetes mellitus, can strongly contribute to ED in patients with CRF. There are many pathophysiological mechanisms that may explain the underlying etiology of diabetic ED. While neuropathy, endocrinopathy and vasculopathy are undoubtedly important, it is becoming increasingly evident that endothelial and smooth muscle function is disordered in diabetes and that this may be the most important factor for the majority of patients with diabetic ED.

**Anemia**

Anemia could contribute to the etiology of ED in men with ESRD because it worsens the poor general condition and causes asthenia in these patients. The treatment of anemia with recombinant erythropoietin in male renal failure patients has been reported to improve their sexual performance. This, however, remains controversial and has led some authors to consider the use of erythropoietin to be inappropriate as a primary treatment.

**Zinc deficiency**

Zinc deficiency has also been suggested as a cause of ED. Uremic patients are often deficient in zinc, probably due to reduced dietary intake and/or zinc malabsorption. In some trials, supplemental zinc resulted in significant increases in potency, libido, and frequency of intercourse. It is possible that normalization of total body zinc may also be effective in correcting uremic hyperprolactinemia and increased plasma testosterone. Some studies support the use of zinc in treatment of ED in dialysis patients, although others showed the absence of a therapeutic effect of zinc in the treatment of ED in dialyzed patients. Because of the difficulty in assessing true tissue zinc levels and the effect of these levels on erectile function, it cannot be concluded that serum or tissue zinc levels are directly responsible for ED and that zinc administration could be expected to produce improvement in erectile function.

**EVALUATION OF ERECTILE DYSFUNCTION IN CRF**

Evaluation should always begin with a systematic history and physical examination. A careful history to identify psychological factors, such as depression, must be carried out. A careful physical examination, including studies for the identification of peripheral neuropathy and vascular abnormalities is important. Hormonal studies, including testosterone, LH, FSH, and prolactin, should be performed. In patients in whom veno-occlusive incompetence or arterial abnormalities are suspected, penile Doppler ultrasound, pharmacocavernosometry, and pharmacocavernosography may be helpful, especially if a surgical intervention is planned. Communication between the nephrologist and transplant surgeon is essential, since transplantation may reverse many of the previously mentioned abnormalities of uremia, and initiation of surgical treatment may be delayed until after transplantation is carried out in some patients.

**TREATMENT OF ED IN CRF**

Treatment of ED in CRF patients must start with the determination and treatment of the underlying causes (Figure 2). The treatment of anemia with recombinant erythropoietin may improve the sexual performance. If the ED is thought to be caused by β-blockers or centrally acting antihypertensives, these can be gradually changed to α-1-adrenergic blockers or calcium channel blockers or angiotensin converting enzyme inhibitors.

Established guidelines recommend that patients with ED of suspected psychogenic origin should initially be offered sexual counseling. However the efficacy of psychotherapy is variable in the treatment of ED, also the acceptability of cost and the availability of qualified counselors may also limit the provision of such therapy. Further lines of treatment of ED in ESRD can be...
programmed sexual activity. Data on the use of these drugs in CRF patients are still lacking. Only one clinical study showed the efficacy and safety of using vardenafil in treating ED in hemodialysis patients\[33\].

**Hormone regulation**

Patients with deficient testosterone levels may be treated with testosterone replacement therapy, which may be beneficial in some cases. Most commonly, testosterone replacement therapy improves libido without significant impact on potency\[36\]. Recently, the efficacy of testosterone gel in the treatment of ED in hypogonadal hemodialysis patients has been shown in a cohort of 96 men with ESRD\[37\].

Pharmacological methods for decreasing hyperprolactinaemia also appear to be effective in some males with uremia-associated sexual dysfunction. Bromocriptine is uniformly effective in normalizing prolactin levels in male dialysis patients with subsequent improvement in libido and potency\[38\]. However, the reported results are variable and the studies that have attempted to evaluate the effect of lowering prolactin levels on sexual dysfunction in male dialysis patients often suffer from methodological problems.

**Vacuum constriction devices**

These devices consist of an elastic band on a cylinder attached to a vacuum pump. The penis is placed in the cylinder and as air is pumped out, the vacuum draws blood into the corpora cavernosa. Once the penis is erect, the elastic band is slipped from the cylinder to the base of the penis, trapping the blood and maintaining the erection. Most manufacturers recommend that the constriction ring should be maintained for less than 30 min.

Lawrence et al\[34\] evaluated the effectiveness of vacuum tumescence therapy in male dialysis patients. Twenty-six patients used the vacuum constriction devices, with 19 (73.1%) having full correction of their ED. A further five predialysis patients used the devices, and all had correction of their ED. The authors concluded that vacuum tumescence therapy corrects ED in most patients\[34\].

**Intracavernosal injection therapy**

A wide variety of drugs are injected intracorporally to induce an adequate erection, the most common of which are prostaglandin E\(1\) (PGE\(1\)), papaverine hydrochloride and phenolamine mesylate. Patient and partner satisfaction is reported as 80%-85%. Side-effects are mainly local and include pain, haematoma or ecchymosis and priapism. Patients with ESRD have a coagulopathy, which is greater in those on hemodialysis and intracavernosal injections should, therefore, be used with caution\[39\]. Contraindications to therapy include poor eye sight, poor manual dexterity, coagulopathy and severe psychiatric disturbances.

**Alprostadil urethral suppository**

Alprostadil may be administered as an intraurethral gel

---

**Figure 2** Lines of treatment of erectile dysfunction in hemodialysis patients. PDE: Phosphodiesterase.

Oral phosphodiesterase type 5 inhibitors

Since 1998 the Food and Drug Administration in the USA has approved three selective PDE type 5 inhibitors (PDE-5I): sildenafil, tadalafil, and vardenafil. Sildenafil citrate was the first PDE-5I introduced to the market. It is an orally active inhibitor of PDE-5; this agent therefore promotes erection by inhibiting the degradation of cGMP. cGMP in turn activates a specific protein kinase which blocks calcium channels and leads to decrease calcium influx. The consequence is a drop in cytosolic calcium concentrations and relaxation of the smooth muscle, thus facilitating the erectile response after sexual stimulation. Possible side effects include vasodilatory effects, such as headache, flushing, nasal congestion, systemic hypotension. Furthermore, the limited selectivity of sildenafil for retinal PDE-6 explains the “blue vision” effect\[26\].

In patients with CRF, the efficacy, safety and tolerability of sildenafil have been thoroughly reported\[27-31\], although strategies for the appropriate timing of drug intake in patients on dialysis programs has not been fully studied. Some authors reported the occurrence of transient hypotension after a 50-mg dose of sildenafil; as patients may remain relatively hypovolemic for some time after dialysis. They recommended that sildenafil should be used on days with no dialysis and that a smaller dose (25 mg) should be used initially\[32\].

Tadalafil and vardenafil are new orally administered potent PDE-5I which are more selective than sildenafil for PDE-6, and should not therefore be associated with the related visual disturbances that occur in some sildenafil-treated patients. Vardenafil, has the highest in vitro potency of all available PDE-5 inhibitors, and tadalafil, has a prolonged half-life that may enable couples to have non-
suppository and reach the corpora cavernosa through direct venous communication. The single-use delivery system consists of an applicator with an alprostadil pellet in its tip. The patient inserts the applicator into the upright penis and rocks the applicator to separate the pellet[37]. Although the system has not been tested in patients with CRF, it has been effective in the treatment of ED arising from most other causes.

**Surgical treatment**

Penile prostheses should only be considered after failure of first and second-line therapies. These procedures should await renal transplantation, since many of men may improve their sexual function after transplantation. However penile prostheses can be successfully implanted without excessive risk of infection in patients with EED and ESRD[38].

**EFFECT OF RENAL TRANSPLANTATION ON ERECTILE FUNCTION**

Renal transplantation greatly improves the overall quality of life for patients with CRF and subsequently it may improve erectile function in a substantial number of renal transplant recipients (RTR), although its specific impact on this issue has been difficult to quantitate.

Some authors reported improvement of erectile function after renal transplantation[19,40]. The improvement of erectile function after transplantation is related to normalization of metabolic and hormonal function[41] and improvement of psychological problems in hemodialyzed patients[42]. On the other hand, others reported a high incidence (40% to 60%) of ED among male RTR[43-45]. The etiology of ED in RTR is often multifactorial and several causal factors have been indicated, including anxiety, medication side effects, interference with penile vasculature, failure to resolve hormonal abnormalities or an underlying disease process, such as DM, hypercholesterolemia, hypertension and atherosclerosis, that has resulted in continued ED[44,45].

**REFERENCES**

1. Cerqueira J, Moraes M, Glinn S. Erectile dysfunction: prevalence and associated variables in patients with chronic renal failure. *Int J Impot Res* 2002; 14: 65-71
2. Malekmakan L, Shakeri S, Haghpanah S, Pakfetrat M, Sarvestani AS, Malekmakan A. Epidemiology of erectile dysfunction in hemodialysis patients using IIEF questionnaire. *Saudi J Kidney Dis Transpl* 2011; 22: 232-236
3. Ali ME, Abdel-Hafez HZ, Mahran AM, Mohamed HZ, Mohamed ER, El-Shazy AM, Gadallah AM, Abbas MA. Erectile dysfunction in chronic renal failure patients undergoing hemodialysis in Egypt. *Int J Impot Res* 2005; 17: 180-185
4. Palmer BF. Sexual dysfunction in uremia. *J Am Soc Nephrol* 1999; 10: 1381-1388
5. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. *N Engl J Med* 1974; 290: 697-701
6. Kaufman JM, Hatzichristou DG, Mulhall JP, Fitch WP, Goldstein I. Impotence and chronic renal failure: a study of the hemodynamic pathophysiology. *J Urol* 1994; 151: 612-618
7. De Broe ME, De Backer WA. Pathophysiology of hemodialysis-associated hypoxemia. *Adv Nephrol Necker Hosp* 1989; 18: 297-315
8. Eckardt KU, Kurtz A. The biological role, site, and regulation of erythropoietin production. *Adv Nephrol Necker Hosp* 1992; 21: 203-233
9. Azadzoi KM, Goldstein I, Siroky MB, Traish AM, Krane RJ, Saenz de Tejada I. Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction. *J Urol* 1998; 160: 2216-2222
10. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. *N Engl J Med* 1989; 321: 1648-1659
11. Campese VM, Procci WR, Levitan D, Romoff MS, Goldstein DA, Massry SG. Autonomic nervous system dysfunction and impotence in uremia. *Am J Nephrol* 1982; 2: 140-143
12. Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. *Drug Saf* 1993; 8: 414-426
13. Rodger RS, Fletcher K, Dewar JH, Gemmer D, McHugh M, Wilkinson R, Ward MK, Kerr DN. Prevalence and pathogenesis of impotence in one hundred uremic men. *Uremia Invest* 1984-1985; 8: 89-96
14. Colin Jones DG, Langman MJ, Lawson DH, Vessey MP. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. *Q J Med* 1985; 54: 253-268
15. Kimmel PL, Weiks H, Peterson RA. Survival in hemodialysis patients: the role of depression. *J Am Soc Nephrol* 1993; 4: 12-27
16. Procci WR, Goldstein DA, Adelstein J, Massry SG. Sexual dysfunction in the male patient with uremia: a reappraisal. *Kidney Int* 1981; 19: 317-323
17. Minhans S, Eardley I, Kirby MG. Erectile dysfunction and diabetes. In: Carson CC, Kirby RS, Goldstein I, Wyllie MG, editors. Text Book of Erectile Dysfunction. 2nd ed. New York: Informa Healthcare, 2009: 449-456
18. Soby MA, Abd el Hamid IA, Atta MG, Refaie AF. Effect of erythropoietin on sexual potency in chronic haemodialysis patients. A preliminary study. *Scand J Urol Nephrol* 1992; 26: 181-185
19. Ayub W, Fletcher S. End-stage renal disease and erectile dysfunction. Is there any hope? *Nephrol Dial Transplant* 2000; 15: 1525-1528
20. Mahajan SK, Abbas AA, Prasad AS, Rabbani P, Briggs WA, McDonald TD. Effect of oral zinc therapy on gonadal function in hemodialysis patients. A double-blind study. *Ann Intern Med* 1982; 97: 357-361
21. Caticha O, Norato DY, Tambascia MA, Santana A, Stephano A, Sarlis NJ. Total body zinc depletion and its relationship to the development of hyperprolactinemia in chronic renal insufficiency. *J Endocrinol Invest* 1996; 19: 441-448
22. Khedun SM, Naicker T, Maharaj B, Zinc, hydrochlorothiazide and sexual dysfunction. *Cent Afr J Med* 1995; 41: 312-315
23. Sprenger KB, Schmitz J, Hezel D, Bundschu D, Franz HE. Zinc and sexual dysfunction. *Conrib Nephrol* 1984; 38: 119-128
24. Carson CC, Lentz AC. Chronic renal failure and sexual dysfunction. In: Carson CC, Kirby RS, Goldstein I, Wyllie MG, editors. Text Book of Erectile Dysfunction. 2nd ed. New York: Informa Healthcare, 2009: 457-467
25. Sachs BD. Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal. *Neurosci Biobehav Rev* 2000; 24: 541-560
26. Boolell M, Allen MJ, Ballard SA, Gepp-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingrich C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. *Int J Impot Res* 1996; 8: 47-52
27. Rosas SE, Wasserstein A, Kobrin S, Feldman HL. Preliminary observations of sildenafil treatment for erectile dysfunction.
in dialysis patients. *Am J Kidney Dis* 2001; 37: 134-137

28 Seibel I, Poli De Figueiredo CE, Telõken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. *J Am Soc Nephrol* 2002; 13: 2770-2775

29 Sahin Y, Aygün C, Peškircioğlu CL, Kut A, Tekin MI, Özdemir FN, Ozkardeş H. Efficacy and safety of sildenafil citrate in hemodialysis patients. *Transplant Proc* 2004; 36: 56-58

30 Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. *Am J Kidney Dis* 2005; 45: 381-387

31 Ghaafari A, Farshid B, Afshari AT, Sepehrvand N, Rikhtegar E, Ghasemi K, Hatami S. Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients. *Indian J Nephrol* 2010; 20: 142-145

32 Mohamed EA, MacDowall P, Coward RA. Timing of sildenafil therapy in dialysis patients-lessons following an episode of hypotension. *Nephrol Dial Transplant* 2000; 15: 926-927

33 Turk S, Solak Y, Kan S, Atalay H, Kilinc M, Agca E, Bodur S. Effects of sildenafil and vardenafil on erectile dysfunction and health-related quality of life in haemodialysis patients: a prospective randomized crossover study. *Nephrol Dial Transplant* 2010; 25: 3729-3733

34 Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescent therapy. *Am J Kidney Dis* 1998; 31: 313-319

35 Cangüven O, Aykose G, Albayrak S, Goktas C, Horuz R, Yençelik F. Efficacy of testosterone gel in the treatment of erectile dysfunction in hypogonadal hemodialysis patients: a pilot study. *Int J Impot Res* 2010; 22: 140-145

36 Muir JW, Besser GM, Edwards CR, Rees LH, Cattell WR, Ackrill P, Baker LR. Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis. *Clin Nephrol* 1983; 20: 308-314

37 Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Luc T, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. *N Engl J Med* 1997; 336: 1-7

38 Ahuja SK, Krane NK, Hellstrom WJ. Penile prostheses in the management of impotence in patients with end-stage renal disease. *J La State Med Soc* 1998; 150: 32-34

39 Tavallaii SA, Mirzamani M, Heshmatzade Behzadi A, Assar S, Khoddami Vishteh HR, Hajarizadeh B, Einollahi B. Sexual function: a comparison between male renal transplant recipients and hemodialysis patients. *J Sex Med* 2009; 6: 142-148

40 Mehrsai A, Mousavi S, Nikoobakh M, Khальнarpoo T, Shekarpour I, Pourmand G. Improvement of erectile dysfunction after kidney transplantation: the role of the associated factors. *Urol J* 2006; 3: 240-244

41 Akbari F, Alavi M, Esteghamati A, Mehrsai A, Djaladat H, Zohrevand R, Pourmand G. Effect of renal transplantation on sperm quality and sex hormone levels. *BJU Int* 2003; 92: 281-283

42 Charmet GP. Sexual function in dialysis patients. Psychological aspects. * Contrib Nephrol* 1990; 77: 15-23

43 Malavaud B, Rostaing L, Tran-Van T, Tack I, Ader JL. Transient renal effects of sildenafil in male kidney transplant recipients. *Transplantation* 2001; 72: 1331-1333

44 El-Bahnasawy MS, El-Assmy A, El-Sawy E, Ali-El Dein B, Shehab El-Dein AB, Refaie A, El-Hammady S. Critical evaluation of the factors influencing erectile function after renal transplantation. *Int J Impot Res* 2004; 16: 521-526

45 Mirone V, Longo N, Fusco F, Verze P, Creta M, Parazzini F, Imbimbo C. Renal transplantation does not improve erectile function in hemodialysed patients. *Eur Urol* 2009; 56: 1047-1053

37 Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Luc T, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. *N Engl J Med* 1997; 336: 1-7

38 Ahuja SK, Krane NK, Hellstrom WJ. Penile prostheses in the management of impotence in patients with end-stage renal disease. *J La State Med Soc* 1998; 150: 32-34

39 Tavallaii SA, Mirzamani M, Heshmatzade Behzadi A, Assar S, Khoddami Vishteh HR, Hajarizadeh B, Einollahi B. Sexual function: a comparison between male renal transplant recipients and hemodialysis patients. *J Sex Med* 2009; 6: 142-148

40 Mehrsai A, Mousavi S, Nikoobakh M, Khальнarpoo T, Shekarpour I, Pourmand G. Improvement of erectile dysfunction after kidney transplantation: the role of the associated factors. *Urol J* 2006; 3: 240-244

41 Akbari F, Alavi M, Esteghamati A, Mehrsai A, Djaladat H, Zohrevand R, Pourmand G. Effect of renal transplantation on sperm quality and sex hormone levels. *BJU Int* 2003; 92: 281-283

42 Charmet GP. Sexual function in dialysis patients. Psychological aspects. *Contrib Nephrol* 1990; 77: 15-23

43 Malavaud B, Rostaing L, Tran-Van T, Tack I, Ader JL. Transient renal effects of sildenafil in male kidney transplant recipients. *Transplantation* 2001; 72: 1331-1333

44 El-Bahnasawy MS, El-Assmy A, El-Sawy E, Ali-El Dein B, Shehab El-Dein AB, Refaie A, El-Hammady S. Critical evaluation of the factors influencing erectile function after renal transplantation. *Int J Impot Res* 2004; 16: 521-526

45 Mirone V, Longo N, Fusco F, Verze P, Creta M, Parazzini F, Imbimbo C. Renal transplantation does not improve erectile function in hemodialysed patients. *Eur Urol* 2009; 56: 1047-1053

S-Editor Wang JL  L-Editor Hughes D  E-Editor Zheng XM